Secondary Progressive Multiple Sclerosis
Neurology·MeSH: Multiple Sclerosis, Chronic Progressive
Prevalence
120.0 / 100K
Incidence
7.0 / 100K/yr
3 drugs in development·2 companies·4 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| orelabrutinib | Zenas BioPharma, Inc. (ZBIO) |
Compare drugs
Frequently asked questions
How many drugs are in development for Secondary Progressive Multiple Sclerosis?
BioSniper tracks 3 drugs in development for Secondary Progressive Multiple Sclerosis across 2 companies.
How many clinical trials target Secondary Progressive Multiple Sclerosis?
There are 4 clinical trials targeting Secondary Progressive Multiple Sclerosis tracked by BioSniper.
What is the prevalence of Secondary Progressive Multiple Sclerosis?
The estimated prevalence of Secondary Progressive Multiple Sclerosis is approximately 120.0 per 100,000 population.
Deep-dive into Secondary Progressive Multiple Sclerosis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis